Table 2.

Prevalence of drug prescriptions during follow-up

	PTX	Non-PTX	P
Baseline
Total patients	257	418
Phosphate binders, %	66	77	0.002
Calcium binders, %	66	36	< .0001
Non calcium based binders, %	85	99	< .0001
Vitamin D, %	41	65	< .0001
Calcitriol (p.o + e.v), %	58	44	0.0039 *
Paricalcitol, %	44	68	0.0384*
Other, %	12	18	0.1313*
Cinacalcet, %	14	34	< .0001
First-year follow-up
Total patients	221	295
Phosphate binders, %	75	89	< .0001
Calcium binders, %	67	41	0.001
Non calcium based binders, %	80	87	0.001
Vitamin D, %	52	68	< .0001
Calcitriol (p.o + e.v), %	57	30	< .0001*
Paricalcitol, %	43	62	0.036*
Other, %	11	25	0.027*
Cinacalcet, %	22	39	< .0001
Second-year follow-up
Total patients	183	230
Phosphate binders, %	83	88	0.001
Calcium based binders, %	68	35	< 0.0001
Non calcium based binders, %	77	84	< 0.0001
Vitamin D, %	61	77	0.0006
Calcitriol (p.o + e.v), %	57	25	< .0001*
Paricalcitol, %	48	67	0.018 *
Other, %	16	29	0.060*
Cinacalcet, %	16	41	< .0001
Third-year follow-up
Total patients	132	144
Phosphate binders, %	71	84	0.014
Calcium based binders, %	62	33	0.0143
Non calcium based binders, %	91	92	0.0143
Vitamin D, %	50	80	< .0001
Calcitriol (p.o + e.v), %	61	21	< .0001*
Paricalcitol, %	28	75	< .0001 *
Other, %	36	27	0.9684*
Cinacalcet, %	19	39	0.0004

Data are shown as percentage. Chi-squared test was used to test for significant differences between groups

^*Bonferroni p-adjusted

Abbreviations: PTX parathyroidectomy